Add Yahoo as a preferred source to see more of our stories on Google. Adam Castillejo, known as "the London Patient," recovered from cancer and HIV following a stem cell transplant. Sabine Dobel/dpa ...

Gilead Sciences, Inc. GILD posted better-than-expected third-quarter 2025 results and lifted the lower end of its product sales. Adjusted earnings per share (EPS) of $2.47 beat the Zacks Consensus ...

A man living with HIV has been declared AIDS-free after receiving a stem cell transplant to treat blood cancer. He becomes the seventh person in the world to be declared HIV-free and only the second ...

Tens of millions of people worldwide live with HIV. Lenacapavir can prevent the virus for months with one injection — a potential game changer. But President Trump and Elon Musk have upended foreign ...

Gilead Sciences, Inc. GILD reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.86, which beat the Zacks Consensus Estimate of $1.83. The bottom line was down from $1.90 reported a ...